FOXO TECHNOLOGIES INC. (FOXO) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
14/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseFOXO / S&P 0.00% / 15.20% |
WinFOXO / S&P 43.99% / 15.00% |
LoseFOXO / S&P FOXO unavailable / 50.40% |
| 2026-Q12/3 |
WinFOXO / S&P 0.00% / -4.33% |
WinFOXO / S&P 154.57% / 11.30% |
LoseFOXO / S&P FOXO unavailable / 27.70% |
| 2025-Q41/3 |
LoseFOXO / S&P -96.43% / 2.65% |
WinFOXO / S&P 303.98% / 9.00% |
LoseFOXO / S&P FOXO unavailable / 13.40% |
| 2025-Q31/3 |
LoseFOXO / S&P -99.23% / 8.12% |
WinFOXO / S&P 1000.04% / 4.61% |
LoseFOXO / S&P FOXO unavailable / 13.45% |
| 2025-Q21/3 |
LoseFOXO / S&P -85.20% / 10.94% |
WinFOXO / S&P 7906.22% / 4.83% |
LoseFOXO / S&P FOXO unavailable / 10.63% |
| 2025-Q11/3 |
LoseFOXO / S&P -57.78% / -4.27% |
WinFOXO / S&P 5072.65% / 4.98% |
LoseFOXO / S&P FOXO unavailable / 10.57% |
| 2024-Q42/3 |
WinFOXO / S&P 53.32% / 2.41% |
WinFOXO / S&P 2688.61% / 5.25% |
LoseFOXO / S&P FOXO unavailable / 6.15% |
| 2024-Q31/3 |
LoseFOXO / S&P -28.46% / 5.89% |
WinFOXO / S&P 196.14% / 5.89% |
LoseFOXO / S&P FOXO unavailable / 6.11% |
| 2024-Q20/3 |
LoseFOXO / S&P -34.74% / 4.28% |
LoseFOXO / S&P -66.10% / 5.38% |
LoseFOXO / S&P FOXO unavailable / 5.12% |
| 2024-Q11/3 |
WinFOXO / S&P 27.31% / 10.56% |
LoseFOXO / S&P -71.18% / 5.71% |
LoseFOXO / S&P FOXO unavailable / 5.59% |
| 2023-Q40/3 |
LoseFOXO / S&P -69.73% / 11.69% |
LoseFOXO / S&P -71.57% / 6.81% |
LoseFOXO / S&P FOXO unavailable / 7.78% |
| 2023-Q31/3 |
LoseFOXO / S&P -65.95% / -3.27% |
WinFOXO / S&P 277.50% / 7.52% |
LoseFOXO / S&P FOXO unavailable / -5.03% |
| 2023-Q21/3 |
LoseFOXO / S&P -26.17% / 8.74% |
WinFOXO / S&P 233.58% / 9.50% |
LoseFOXO / S&P FOXO unavailable / -8.57% |
| 2023-Q11/3 |
WinFOXO / S&P 10.82% / 7.50% |
LoseFOXO / S&P FOXO unavailable / 10.77% |
LoseFOXO / S&P FOXO unavailable / -15.69% |
| 2022-Q40/3 |
LoseFOXO / S&P -70.39% / 7.56% |
LoseFOXO / S&P FOXO unavailable / 11.88% |
LoseFOXO / S&P FOXO unavailable / -17.99% |
| 2022-Q30/3 |
LoseFOXO / S&P FOXO unavailable / -4.88% |
LoseFOXO / S&P FOXO unavailable / 13.47% |
LoseFOXO / S&P FOXO unavailable / -1.41% |
| 2022-Q20/3 |
LoseFOXO / S&P FOXO unavailable / -16.10% |
LoseFOXO / S&P FOXO unavailable / 13.71% |
LoseFOXO / S&P FOXO unavailable / 11.04% |
| 2022-Q10/3 |
LoseFOXO / S&P FOXO unavailable / -4.60% |
LoseFOXO / S&P FOXO unavailable / 15.97% |
LoseFOXO / S&P FOXO unavailable / 42.23% |
| 2021-Q40/3 |
LoseFOXO / S&P FOXO unavailable / 11.03% |
LoseFOXO / S&P FOXO unavailable / 15.00% |
LoseFOXO / S&P FOXO unavailable / 96.40% |
| 2021-Q30/3 |
LoseFOXO / S&P FOXO unavailable / 0.58% |
LoseFOXO / S&P FOXO unavailable / 10.77% |
LoseFOXO / S&P FOXO unavailable / 69.42% |
| 2021-Q20/3 |
LoseFOXO / S&P FOXO unavailable / 8.55% |
LoseFOXO / S&P FOXO unavailable / 6.58% |
LoseFOXO / S&P FOXO unavailable / 51.81% |
| 2021-Q10/3 |
LoseFOXO / S&P FOXO unavailable / 6.17% |
LoseFOXO / S&P FOXO unavailable / -1.06% |
LoseFOXO / S&P FOXO unavailable / 7.39% |
| 2020-Q40/3 |
LoseFOXO / S&P FOXO unavailable / 12.15% |
LoseFOXO / S&P FOXO unavailable / -3.72% |
LoseFOXO / S&P FOXO unavailable / -33.42% |
| 2020-Q30/3 |
LoseFOXO / S&P FOXO unavailable / 8.93% |
LoseFOXO / S&P FOXO unavailable / -2.04% |
LoseFOXO / S&P FOXO unavailable / -27.10% |
| 2020-Q20/3 |
LoseFOXO / S&P FOXO unavailable / 20.54% |
LoseFOXO / S&P FOXO unavailable / -0.46% |
LoseFOXO / S&P FOXO unavailable / -27.11% |
| 2020-Q10/3 |
LoseFOXO / S&P FOXO unavailable / -19.60% |
LoseFOXO / S&P FOXO unavailable / 3.47% |
LoseFOXO / S&P FOXO unavailable / -14.75% |
| 2019-Q40/3 |
LoseFOXO / S&P FOXO unavailable / 9.07% |
LoseFOXO / S&P FOXO unavailable / 5.36% |
LoseFOXO / S&P FOXO unavailable / 2.99% |
| 2019-Q30/3 |
LoseFOXO / S&P FOXO unavailable / 1.70% |
LoseFOXO / S&P FOXO unavailable / 5.02% |
LoseFOXO / S&P FOXO unavailable / 0.21% |
| 2019-Q20/3 |
LoseFOXO / S&P FOXO unavailable / 4.30% |
LoseFOXO / S&P FOXO unavailable / 6.64% |
LoseFOXO / S&P FOXO unavailable / 8.65% |
| 2019-Q10/3 |
LoseFOXO / S&P FOXO unavailable / 13.65% |
LoseFOXO / S&P FOXO unavailable / 8.12% |
LoseFOXO / S&P FOXO unavailable / 14.29% |
| 2018-Q40/3 |
LoseFOXO / S&P FOXO unavailable / -13.52% |
LoseFOXO / S&P FOXO unavailable / 9.05% |
LoseFOXO / S&P FOXO unavailable / 18.23% |
| 2018-Q30/3 |
LoseFOXO / S&P FOXO unavailable / 7.71% |
LoseFOXO / S&P FOXO unavailable / 10.21% |
LoseFOXO / S&P FOXO unavailable / 19.06% |
| 2018-Q20/3 |
LoseFOXO / S&P FOXO unavailable / 3.43% |
LoseFOXO / S&P FOXO unavailable / 9.03% |
LoseFOXO / S&P FOXO unavailable / 14.46% |
| 2018-Q10/3 |
LoseFOXO / S&P FOXO unavailable / -0.76% |
LoseFOXO / S&P FOXO unavailable / 7.68% |
LoseFOXO / S&P FOXO unavailable / 12.46% |
| 2017-Q40/3 |
LoseFOXO / S&P FOXO unavailable / 6.64% |
LoseFOXO / S&P FOXO unavailable / 7.03% |
LoseFOXO / S&P FOXO unavailable / 13.82% |
| 2017-Q30/3 |
LoseFOXO / S&P FOXO unavailable / 4.48% |
LoseFOXO / S&P FOXO unavailable / 5.68% |
LoseFOXO / S&P FOXO unavailable / 17.57% |
| 2017-Q20/3 |
LoseFOXO / S&P FOXO unavailable / 3.09% |
LoseFOXO / S&P FOXO unavailable / 4.83% |
LoseFOXO / S&P FOXO unavailable / 17.74% |
| 2017-Q10/3 |
LoseFOXO / S&P FOXO unavailable / 6.07% |
LoseFOXO / S&P FOXO unavailable / 3.67% |
LoseFOXO / S&P FOXO unavailable / 13.32% |
| 2016-Q40/3 |
LoseFOXO / S&P FOXO unavailable / 3.82% |
LoseFOXO / S&P FOXO unavailable / 2.09% |
LoseFOXO / S&P FOXO unavailable / 7.05% |
| 2016-Q30/3 |
LoseFOXO / S&P FOXO unavailable / 3.85% |
LoseFOXO / S&P FOXO unavailable / 0.20% |
LoseFOXO / S&P FOXO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | FOXO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.55% | 20.78% |
| Annualized return | -99.55% | 20.78% |
5Y · 2022-09-19 to 2026-08-28
| Metric | FOXO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 83.14% |
| Annualized return | -96.37% | 12.86% |
10Y · 2022-09-19 to 2026-08-28
| Metric | FOXO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -80.95% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |